Notice_of_Intent_to_Sole_Source.doc

/ DEPARTMENT OF HEALTH & HUMAN SERVICES

Food & Drug Administration

Memorandum

Notice of Intent to Sole Source

FDA-2014-RFQ-1135076

Notice of Intent to Sole Source – Illumina Corporation Inc.

The Food and Drug Administration intends to award a Sole Source firm-fixed price purchase order to Illumina Corporation Inc.,) located at: 5200 Illumina Way, San Diego, CA 92122.

In accordance with FAR part 6.302-1, there is only one responsible source and no other supplies or services will satisfy agency requirements: Illumina Corporation Inc.

The purpose of this acquisition is for the purchase of Illimuna NextSeq High Output Reagents with multiple delivery dates. Illumina sequencing kits use an all-inclusive reagent cartridge system that is specifically designed to deliver the reagents necessary for cluster generation, sequencing, and paired-end chemistry. In addition, the NextSeq 500 system uses a flow cell that is specifically designed for the instrument. Illumina is the only manufacturer who can provide these reagent kits compatible with the NextSeq 500 sequencer instrument that FDA/CVM has in the laboratory.

The associated NAICS Code is: 334516 Analytical Laboratory Instrument Manufacturing.

This notice is not a request for competitive proposals. However, any party that believes it is capable of meeting this requirement as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to perform the requirement. Capability statements must be received by the response date and time of this notice. Submissions will be reviewed to determine if they can meet the requirement. A determination by the Government to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.

It is anticipated that an award will be issued to Illumina Corporation Inc., within approximately fifteen (15) days after the date of this notice unless the Government determines that any other organization has the capacity to meet this requirement.

Response Date: 12:00 p.m. EST 06/30/2014. Please email responses to Emmanuel Mbah at Emmanuel.mbah@fda.hhs.gov � EMBED Word.Picture.8 ���

_1182589260.doc